Skip Navigation


JAC Advance Access originally published online on September 28, 2008
Journal of Antimicrobial Chemotherapy 2008 62(6):1462-1463; doi:10.1093/jac/dkn414
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
62/6/1462    most recent
dkn414v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tobin, C. M.
Right arrow Articles by MacGowan, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tobin, C. M.
Right arrow Articles by MacGowan, A. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

An HPLC assay for daptomycin in serum

C. M. Tobin*, J. M. Darville, A. M. Lovering and A. P. MacGowan

Bristol Centre for Antimicrobial Research and Evaluation, Microbiology Department, Southmead Hospital, North Bristol NHS Trust, Bristol BS10 5NB, UK

* Corresponding author. Tel: +44-117-9505050, ext. 4311; Fax: +44-117-9592317; E-mail: caroline.tobin@nbt.nhs.uk

Keywords: therapeutic drug monitoring , antibiotics , pharmacokinetics

The first 10% of the full text of this article appears below.

Sir,

The lipopeptides have a unique mode of action.1 Although they are active against all clinically important Gram-positive bacteria,2 they display no activity against Gram-negative organisms.3,4 Daptomycin has been licensed for the treatment of complicated skin and skin structure infections, and for right-sided endocarditis. The approved dosage in the UK is 4 mg/kg daily. For Staphylococcus aureus bacteraemia and endocarditis, a dosage of 6 mg/kg daily is advised (British National Formulary 55, March . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?